This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med 2012; 366(9): 780–1. doi: 10.1056/NEJMp1109283.BarryMJEdgman-LevitanSShared decision making--pinnacle of patient-centered care20123669780110.1056/NEJMp110928322375967Open DOISearch in Google Scholar
Karazivan P, Dumez V, Flora L, et al. The patient-as-partner approach in health care: a conceptual framework for a necessary transition. Acad Med 2015; 90(4): 437–41. doi: 10.1097/ACM.0000000000000603.KarazivanPDumezVFloraLThe patient-as-partner approach in health care: a conceptual framework for a necessary transition20159044374110.1097/ACM.000000000000060325607943Open DOISearch in Google Scholar
Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Ther Adv Hematol 2018; 9(8): 239–249. doi: 10.1177/2040620718784830.NossairFThornburgCDThe role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries20189823924910.1177/2040620718784830611675730181844Open DOISearch in Google Scholar
Fillion E. How is medical decision-making shared? The case of haemophilia patients and doctors: the aftermath of the infected blood affair in France. Health Expect 2003; 6(3): 228–41. doi: 10.1046/j.1369-6513.2003.00244.x.FillionEHow is medical decision-making shared? The case of haemophilia patients and doctors: the aftermath of the infected blood affair in France2003632284110.1046/j.1369-6513.2003.00244.x506018112940796Open DOISearch in Google Scholar
Berger Z. Navigating the unknown: shared decision-making in the face of uncertainty. J Gen Intern Med 2015; 30(5): 675–8. doi: 10.1007/s11606-014-3074-8.BergerZNavigating the unknown: shared decision-making in the face of uncertainty2015305675810.1007/s11606-014-3074-8439558925536912Open DOISearch in Google Scholar
Montori VM, Gafni A, Charles C. A shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetes. Health Expect 2006; 9(1): 25–36. doi: 10.1111/j.1369-7625.2006.00359.x.MontoriVMGafniACharlesCA shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetes200691253610.1111/j.1369-7625.2006.00359.x506032316436159Open DOISearch in Google Scholar
Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012; 27(10): 1361–7. doi: 10.1007/s11606-012-2077-6.ElwynGFroschDThomsonRShared decision making: a model for clinical practice201227101361710.1007/s11606-012-2077-6344567622618581Open DOISearch in Google Scholar
Hauser K, Koerfer A, Kuhr K, Albus C, Herzig S, Matthes J. Outcome-relevant effects of shared decision making. Dtsch Arztebl Int 2015; 112(40): 665–71. doi: 10.3238/arztebl.2015.0665.HauserKKoerferAKuhrKAlbusCHerzigSMatthesJOutcome-relevant effects of shared decision making2015112406657110.3238/arztebl.2015.0665464007026517594Open DOISearch in Google Scholar
Matlock DD, Spatz ES. Design and testing of tools for shared decision making. Circ Cardiovasc Qual Outcomes 2014; 7(3): 487–92. doi: 10.1161/CIRCOUTCOMES.113.000289.MatlockDDSpatzESDesign and testing of tools for shared decision making2014734879210.1161/CIRCOUTCOMES.113.00028924714602Open DOISearch in Google Scholar
Drug and Therapeutics Bulletin. An introduction to patient decision aids. BMJ 2013; 347: f4147. doi: 10.1136/bmj.f4147.Drug and Therapeutics BulletinAn introduction to patient decision aids2013347f414710.1136/bmj.f414723881944Open DOISearch in Google Scholar
Agency for Healthcare Research and Quality. The SHARE Approach. Available from https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html (accessed 28 March 2019).Agency for Healthcare Research and QualityAvailable from https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html (accessed 28 March 2019).Search in Google Scholar
Lamiani G, Bigi S, Mancuso ME, Coppola A, Vegni E. Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication. Patient Educ Couns 2017; 100(4): 690–695. doi: 10.1016/j.pec.2016.11.021.LamianiGBigiSMancusoMECoppolaAVegniEApplying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication2017100469069510.1016/j.pec.2016.11.021Open DOISearch in Google Scholar
Dolan JG. Shared decision-making--transferring research into practice: the Analytic Hierarchy Process (AHP). Patient Educ Couns 2008; 73(3): 418–25. doi: 10.1016/j.pec.2008.07.032.DolanJGShared decision-making--transferring research into practice: the Analytic Hierarchy Process (AHP)20087334182510.1016/j.pec.2008.07.032Open DOISearch in Google Scholar
Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making 2015; 35(1): 114–31. doi: 10.1177/0272989X14551638.ShayLALafataJEWhere is the evidence? A systematic review of shared decision making and patient outcomes20153511143110.1177/0272989X14551638Open DOISearch in Google Scholar
Beers E, Nilsen ML, Johnson JT. The role of patients: shared decision-making. Otolaryngol Clin North Am 2017; 50(4): 689–708. doi: 10.1016/j.otc.2017.03.006.BeersENilsenMLJohnsonJTThe role of patients: shared decision-making201750468970810.1016/j.otc.2017.03.006Open DOISearch in Google Scholar
Del Río-Lanza AB, Suárez-Álvarez L, Suárez-Vázquez A, Vázquez-Casielles R. Information provision and attentive listening as determinants of patient perceptions of shared decision-making around chronic illnesses. Springerplus 2016; 5(1): 1386. doi: 10.1186/s40064-016-3086-4.Del Río-LanzaABSuárez-ÁlvarezLSuárez-VázquezAVázquez-CasiellesRInformation provision and attentive listening as determinants of patient perceptions of shared decision-making around chronic illnesses201651138610.1186/s40064-016-3086-4Open DOISearch in Google Scholar
Joseph-Williams N, Lloyd A, Edwards A, et al. Implementing shared decision making in the NHS: lessons from the MAGIC programme. BMJ 2017; 357: j1744. doi: 10.1136/bmj.j1744.Joseph-WilliamsNLloydAEdwardsAImplementing shared decision making in the NHS: lessons from the MAGIC programme2017357j174410.1136/bmj.j1744Open DOISearch in Google Scholar
Epstein RM. Whole mind and shared mind in clinical decision-making. Patient Educ Couns 2013; 90(2): 200–6. doi: 10.1016/j.pec.2012.06.035.EpsteinRMWhole mind and shared mind in clinical decision-making2013902200610.1016/j.pec.2012.06.035Open DOISearch in Google Scholar
Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am J Prev Med 1999; 17(4): 285–94. doi: 10.1016/s0749-3797(99)00097-5.FroschDLKaplanRMShared decision making in clinical medicine: past research and future directions19991742859410.1016/s0749-3797(99)00097-5Open DOISearch in Google Scholar
Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. Implementation Sci 2015; 11: 114. doi: 10.1186/s13012-016-0480-9.ElwynGFroschDLKobrinSImplementing shared decision-making: consider all the consequences20151111410.1186/s13012-016-0480-9497765027502770Open DOISearch in Google Scholar
Barratt A. Evidence based medicine and shared decision making: the challenge of getting both evidence and preferences into health care. Patient Educ Couns 2008; 73(3): 407–12. doi: 10.1016/j.pec.2008.07.054.BarrattAEvidence based medicine and shared decision making: the challenge of getting both evidence and preferences into health care20087334071210.1016/j.pec.2008.07.05418845414Open DOISearch in Google Scholar
National Hemophilia Foundation. MASAC Document #241 – Recommendation concerning prophylaxis. February 28, 2016. Available from http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007 (accessed 23 June 2016).National Hemophilia FoundationFebruary 28, 2016. Available from http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007 (accessed 23 June 2016).Search in Google Scholar
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al.; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): e1–e47. doi: 10.1111/j.1365-2516.2012.02909.x.SrivastavaABrewerAKMauser-BunschotenEPTreatment Guidelines Working Group on Behalf of the World Federation of HemophiliaGuidelines for the management of hemophilia2013191e1e4710.1111/j.1365-2516.2012.02909.x22776238Open DOISearch in Google Scholar
Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl 4): 131–5. doi: 10.1111/j.1365-2516.2012.02838.x.CollinsPWPersonalized prophylaxis201218Suppl 4131510.1111/j.1365-2516.2012.02838.x22726096Open DOISearch in Google Scholar
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia 2014; 20(5): 607–15. doi: 10.1111/hae.12438.ValentinoLAConsiderations in individualizing prophylaxis in patients with haemophilia A20142056071510.1111/hae.1243824712891Open DOISearch in Google Scholar
Simhadri VL, Banerjee AS, Simon J, Kimchi-Sarfaty C, Sauna ZE. Personalized approaches to the treatment of hemophilia A and B. Per Med 2015; 12(4): 403–415. doi: 10.2217/pme.15.6.SimhadriVLBanerjeeASSimonJKimchi-SarfatyCSaunaZEPersonalized approaches to the treatment of hemophilia A and B201512440341510.2217/pme.15.629771661Open DOISearch in Google Scholar
Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10(3): 359–67. doi: 10.1111/j.1538-7836.2011.04611.x.ValentinoLAMamonovVHellmannAA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management20121033596710.1111/j.1538-7836.2011.04611.x348830122212248Open DOISearch in Google Scholar
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123(3): 317–25. doi: 10.1182/blood-2013-10-529974.MahlanguJPowellJSRagniMVPhase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A201412333172510.1182/blood-2013-10-529974389449124227821Open DOISearch in Google Scholar
Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood 2019; 133(5): 407–14. doi: 10.1182/blood-2018-07-820720.PerrinGQHerzogRWMarkusicDMUpdate on clinical gene therapy for hemophilia201913354071410.1182/blood-2018-07-820720635698530559260Open DOISearch in Google Scholar
Rodriguez-Merchan EC, Valentino LA. Emicizumab: Review of the literature and critical appraisal. Haemophilia 2019; 25(1): 11–20. doi: 10.1111/hae.13641.Rodriguez-MerchanECValentinoLAEmicizumab: Review of the literature and critical appraisal2019251112010.1111/hae.1364130431213Open DOISearch in Google Scholar
Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7(4): 392–6. doi: 10.1046/j.1365-2516.2001.00534.x.HackerMRGeraghtySManco-JohnsonMBarriers to compliance with prophylaxis therapy in haemophilia200174392610.1046/j.1365-2516.2001.00534.x11442644Open DOISearch in Google Scholar
De Moerloose P, Urbancik W, Van Den Berg HM, Richards M.A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14(5): 931–8. doi: 10.1111/j.1365-2516.2008.01843.x.De MoerloosePUrbancikWVan Den BergHMRichardsMA survey of adherence to haemophilia therapy in six European countries: results and recommendations2008145931810.1111/j.1365-2516.2008.01843.x18684125Open DOISearch in Google Scholar
Du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13(5): 493–501. doi: 10.1111/j.1365-2516.2007.01526.x.Du TreilSRiceJLeissingerCAQuantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population200713549350110.1111/j.1365-2516.2007.01526.x17880435Open DOISearch in Google Scholar
Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18(4): 568–74. doi: 10.1111/j.1365-2516.2012.02756.x.ThornburgCDCarpenterSZappaSMunnJLeissingerCCurrent prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States20121845687410.1111/j.1365-2516.2012.02756.x22335526Open DOISearch in Google Scholar
Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv 2018; 2(14): 1792–1798. doi: 10.1182/bloodadvances.2018021345.MachinNRagniMVSmithKJGene therapy in hemophilia A: a cost-effectiveness analysis20182141792179810.1182/bloodadvances.2018021345605823630042145Open DOISearch in Google Scholar
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357(6): 535–44. doi: 10.1056/NEJMoa067659.Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia200735765354410.1056/NEJMoa06765917687129Open DOISearch in Google Scholar
Ellis AG, Mickle K, Herron-Smith S, et al. Spinraza® and Zolgensma® for spinal muscular atrophy: effectiveness and value. Final evidence report. Institue for Clinical and Economic Review, April 3, 2019. Available from https://34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/ICER_SMA_Final_Evidence_Report_110220.pdf (accessed 28 April 2021).EllisAGMickleKHerron-SmithSSpinraza® and Zolgensma® for spinal muscular atrophy: effectiveness and value. Final evidence reportApril32019Available from https://34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/ICER_SMA_Final_Evidence_Report_110220.pdf (accessed 28 April 2021).Search in Google Scholar
Pierce GF. Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns. Haemophilia 2020; 27 (S3): 103–13. doi: 10.1111/hae.14023.PierceGFUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns202027S31031310.1111/hae.1402332484283Open DOISearch in Google Scholar
Pierce GF, Pasi KJ, Coffin D, et al.; Members of the WFH Gene Therapy Round Table Program Organizing Committee. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia 2020; 26(3): 443–449. doi: 10.1111/hae.13971.PierceGFPasiKJCoffinDMembers of the WFH Gene Therapy Round Table Program Organizing CommitteeTowards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table202026344344910.1111/hae.1397132202382Open DOISearch in Google Scholar
US Food & Drug Administration. FDA approves emicizumabkxwh for hemophilia A with or without factor VIII inhibitors. 14 December 2018. Available from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumabkxwh-hemophilia-or-without-factor-viii-inhibitors (accessed 23 October 2019).US Food & Drug Administration14 December 2018. Available from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumabkxwh-hemophilia-or-without-factor-viii-inhibitors (accessed 23 October 2019).Search in Google Scholar
HEMLIBRA®. HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use [package insert]. Genentech, Inc., South San Francisco, CA, October 2018.HEMLIBRA®Genentech, Inc.South San Francisco, CAOctober2018Search in Google Scholar
Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: a current update. Blood Transfus 2018; 16(5): 457–461. doi: 10.2450/2018.0272-17.FranchiniMMannucciPMNon-factor replacement therapy for haemophilia: a current update201816545746110.2450/2018.0272-17612523029517971Open DOISearch in Google Scholar
High KA, Roncarolo MG. Gene therapy. N Engl J Med 2019; 381(5): 455–464. doi: 10.1056/NEJMra1706910.HighKARoncaroloMGGene therapy2019381545546410.1056/NEJMra170691031365802Open DOISearch in Google Scholar
Patel U, Boucher M, de Leseleuc L, Visintini S. Voretigene neparvovec: An emerging gene therapy for the treatment of inherited blindness. 2018 Mar 1. In: CADTH Issues in Emerging Health Technologies, Ottawa (ON) 2016–; 169.PatelUBoucherMde LeseleucLVisintiniS2018Mar1In:CADTH Issues in Emerging Health TechnologiesOttawa (ON)2016169Search in Google Scholar
ZOLGENSMA®, ZOLGENSMA® (onasemnogene abeparvovecxioi) suspension for intravenous infusion [package insert]. AveXis, In., Bannockburn, IL, 2019.ZOLGENSMA®AveXis, In.Bannockburn, IL2019Search in Google Scholar
Brimble MA, Reiss UM, Nathwani AC, Davidoff AM. New and improved AAVenues: current status of hemophilia B gene therapy. Expert Opin Biol Ther 2016; 16(1): 79–92. doi: 10.1517/14712598.2015.1106475.BrimbleMAReissUMNathwaniACDavidoffAMNew and improved AAVenues: current status of hemophilia B gene therapy2016161799210.1517/14712598.2015.110647526524468Open DOISearch in Google Scholar
High KA, Skinner MW. Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia. Mol Ther 2011; 19(10): 1749–50. doi: 10.1038/mt.2011.203.HighKASkinnerMWCell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia2011191017495010.1038/mt.2011.203318875421964303Open DOISearch in Google Scholar
Pipe SW. Gene therapy for hemophilia. Pediatr Blood Cancer 2018; 65(2). doi: 10.1002/pbc.26865.PipeSWGene therapy for hemophilia201865210.1002/pbc.2686529077262Open DOISearch in Google Scholar
Iorio A, Skinner MW, Clearfield E, et al.; coreHEM panel. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia 2018; 24(4): e167–e172. doi: 10.1111/hae.13504.IorioASkinnerMWClearfieldEcoreHEM panelCore outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project2018244e167e17210.1111/hae.1350429781145Open DOISearch in Google Scholar
Sun HL, McIntosh KA, Squire SJ, et al. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia 2017; 23(6): 877–883. doi: 10.1111/hae.13319.SunHLMcIntoshKASquireSJPatient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A201723687788310.1111/hae.1331928851133Open DOISearch in Google Scholar
Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood 2017; 130(21): 2251–2256. doi: 10.1182/blood-2017-08-742312.ArrudaVRDoshiBSSamelson-JonesBJNovel approaches to hemophilia therapy: successes and challenges2017130212251225610.1182/blood-2017-08-742312581373529018078Open DOISearch in Google Scholar
Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia 2018; 24 Suppl 6: 60–67. doi: 10.1111/hae.13489.PierceGFIorioAPast, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes201824Suppl 6606710.1111/hae.1348929878660Open DOISearch in Google Scholar
American Society of Gene & Cell Therapy. Gene Therapy 101. Available from https://www.asgct.org/education/gene-therapy-101 (accessed 17 October 2019.American Society of Gene & Cell TherapyAvailable from https://www.asgct.org/education/gene-therapy-101 (accessed 17 October 2019.Search in Google Scholar
Klifto K, Klifto C, Slover J. Current concepts of shared decision making in orthopedic surgery. Curr Rev Musculoskelet Med 2017; 10(2): 253–257. doi: 10.1007/s12178-017-9409-4.KliftoKKliftoCSloverJCurrent concepts of shared decision making in orthopedic surgery201710225325710.1007/s12178-017-9409-4543564028337730Open DOISearch in Google Scholar
Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin North Am 2017; 31(5): 853–868. doi: 10.1016/j.hoc.2017.06.011.NathwaniACDavidoffAMTuddenhamEGDGene therapy for hemophilia201731585386810.1016/j.hoc.2017.06.01128895852Open DOISearch in Google Scholar
Stoffman J, Andersson NG, Branchford B, et al. Common themes and challenges in hemophilia care: a multinational perspective. Hematology 2019; 24(1): 39–48. doi: 10.1080/10245332.2018.1505225.StoffmanJAnderssonNGBranchfordBCommon themes and challenges in hemophilia care: a multinational perspective2019241394810.1080/10245332.2018.150522530073913Open DOISearch in Google Scholar